logo-loader
viewValiRx PLC

ValiRx has raised £1.15mln via a share placing to accelerate its clinical and pre-clinical portfolio

The AIM-listed firm said it issued 76,666,666 new ordinary shares at a price of 1.50p each in the placing undertaken by the company's broker, Novum Securities

Cancer cells
ValiRx said the net proceeds will be used to extend and expand the scope of the clinical trial of VAL201 to treat prostate cancer

ValiRx PLC (LON:VAL), the clinical stage biotechnology company, has raised £1.15mln via a placing to accelerate its clinical and pre-clinical portfolio, welcoming new investors in the process.

The AIM-listed firm said it issued 76,666,666 new ordinary shares at a price of 1.50p each in the placing undertaken by the company's broker, Novum Securities.

WATCH: Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

The group said the net proceeds of the placing will be used to extend and expand the scope of the clinical trial of VAL201 to treat prostate cancer and to thereby allow the treatment to more speedily reach its full therapeutic potential and potential anti-cancer impact. 

It added that the funds will also be used to progress the development of the pre-clinical VAL301 and VAL101 programmes and towards clinical trials.

Dr Satu Vainikka, ValiRx’s CEO commented: "I am grateful for the support we have received from both new and existing investors and their investment will enable the Company to further progress and accelerate its clinical and pre-clinical portfolio, namely VAL101, 201 and 301 and move these therapeutic assets closer to their respective value inflection points".

Quick facts: ValiRx PLC

Price: 0.23 GBX

AIM:VAL
Market: AIM
Market Cap: £2.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read